Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Acromegaly

Therapeutic area intelligence for Acromegaly with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Companies

No related entities indexed yet.

ClinicalAugust 2, 2026

A clinical trial has been initiated to evaluate the safety and tolerability of MAR002 administered subcutaneously in patients with acromegaly.

RegulatoryJune 30, 2026

PALSONIFY is indicated for adults with acromegaly who have not responded adequately to surgery or are not surgical candidates.

No catalysts indexed for this entity yet.

No related entities indexed yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.